Articles Tagged With:
-
Were study’s findings misleading?
The “slanting” of data published in the scientific literature was recently spotlighted after an independent analysis suggested a psychiatric drug did not show efficacy, contradicting a previous study’s conclusions.
-
Growing evidence that teleconsultation can support palliative care provision
There is growing evidence that telepalliative care consultation is an effective approach, but fee-for-service systems and lack of reimbursement are obstacles.
-
Surprising data on nursing homes and “culture change”
Some nursing homes that rely heavily on Medicaid funding have implemented “culture change” or palliative care, a recent study found.
-
Access to mental healthcare is “question of social justice”
Access to equal benefits and qualified providers remains difficult for many insured Americans, despite the Mental Health Parity and Addiction Equity Act of 2008, according to a recent health policy brief.
-
Many oncologists being asked to solicit donations from patients
About one-third of oncologists had been asked to directly solicit a donation from their patients for their institutions, according to a recent study - and half declined to do so.
-
Ethical approaches to disclose errors made by other clinicians
Physicians face a number of personal and ethical challenges in disclosing medical errors made by a colleague.
-
The Challenge of Advance Care Planning Billing
Providers can now bill Medicare for advance care planning, eliminating one important barrier to end-of-life conversations.
-
The Vitals - December 2015
-
Ceftazidime-avibactam — Formulary Considerations
Ceftazidime-avibactam is a new beta-lactam/beta-lactamase inhibitor combination approved for the treatment of complicated intra-abdominal infections in combination with metronidazole, and complicated urinary tract infections, including pyelonephritis in patients with limited alternative treatment options.
-
Idarucizumab Injection (Praxbind)
The FDA has approved the first reversal agent for a direct oral anticoagulant. Idarucizumab is a humanized monoclonal antibody fragment derived from an IgG1 isotype molecule.